<DOC>
	<DOCNO>NCT00418782</DOCNO>
	<brief_summary>CE-224535 new medication develop analgesic anti-inflammatory agent treatment sign symptom osteoarthritis ( OA ) . The purpose study evaluate analgesic anti inflammatory efficacy safety CE 224,535 versus placebo naproxen treatment patient OA knee pain .</brief_summary>
	<brief_title>A Study Of The Effect Of CE-224535 On Knee OA ( Osteoarthritis ) Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Is healthy adult 18 75 year age , inclusive , general good health diagnosis knee OA , determine American College Rheumatology ( ACR ) clinical/radiographic classification criterion OA knee . Women must non childbearing potential ( amenorrhea least 1 year PLUS serum follicle stimulate hormone ( FSH ) level &gt; 30 IU/L , bilateral oophorectomy hysterectomy ) , confirm negative serum pregnancy test screen visit prior randomization . History disease may involve study joint , include inflammatory joint disease , crystalline disease , endocrinopathies , metabolic disease , infection , neuropathic disorder , avascular necrosis , Paget 's disease , tumor . Women childbearing potential , pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>